Related Experiment Video
Updated: May 8, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
A Lucknolide Derivative Induces Mitochondrial ROS-Mediated G2/M Arrest and Apoptotic Cell Death in B16F10 Mouse
Jae Hyeop Lee1, Byeoung-Kyu Choi2, Minsoo Kim3
1BB21 Plus Program, Department of Chemistry, Pukyong National University, Busan 48513, Republic of Korea.
Abstract:
Melanoma is an aggressive skin cancer with a high risk of cancer-related deaths, and inducing apoptosis in melanoma cells is a promising therapeutic strategy. This study investigates the anti-tumor potential of a novel lucknolide derivative LA-UC as a therapeutic candidate for melanoma. Lucknolide A (LA), a tricyclic ketal-lactone metabolite isolated from marine-derived Streptomyces sp., was chemically modified by introducing a 10-undecenoyl group to synthesize LA-UC. LA-UC preferentially inhibited the proliferation of melanoma cells, including B16F10, while exerting minimal effects on normal melanocytes or other tumor cell types, indicating the selective action of LA-UC against melanoma cells. LA-UC decreased G2/M checkpoint proteins, including cyclin B1 and Cdc2, while activating caspase-3 and caspase-9, resulting in G2/M cell cycle arrest and inducing apoptotic cell death in B16F10 cells. The addition of a pan-caspase inhibitor confirmed the caspase-dependent mechanism of LA-UC-induced cell death. Additionally, LA-UC elevated mitochondrial ROS levels, leading to mitochondrial membrane disruption, upregulation of pro-apoptotic proteins, and DNA damage in melanoma cells. The ROS scavenger N-acetylcysteine reduced LA-UC-induced mitochondrial ROS accumulation, mitochondrial membrane disruption, DNA damage, and apoptosis. Collectively, these findings suggest that LA-UC induces G2/M cell cycle arrest and caspase-dependent apoptosis in B16F10 cells through excessive mitochondrial ROS generation, membrane impairment, and DNA damage, highlighting its potential as a promising therapeutic candidate for melanoma treatment.
Insights
A novel compound, LA-UC, selectively targets and kills melanoma cells by inducing cell cycle arrest and apoptosis. This process involves mitochondrial reactive oxygen species generation and DNA damage, suggesting LA-UC as a potential melanoma therapy.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Melanoma is an aggressive skin cancer with a high mortality rate.
- Inducing apoptosis (programmed cell death) in melanoma cells is a key therapeutic strategy.
- Marine-derived compounds offer potential for novel cancer treatments.
Purpose of the Study:
- To investigate the anti-tumor potential of a novel lucknolide derivative, LA-UC, against melanoma.
- To elucidate the mechanism of action of LA-UC in melanoma cells.
Main Methods:
- Chemical synthesis of LA-UC from Lucknolide A.
- In vitro assessment of LA-UC's effects on melanoma cells (B16F10) and normal cells.
- Analysis of cell cycle proteins (cyclin B1, Cdc2), caspase activation (caspase-3, caspase-9), and reactive oxygen species (ROS) levels.
- Evaluation of mitochondrial membrane potential and DNA damage.
- Use of a pan-caspase inhibitor and ROS scavenger (N-acetylcysteine) to confirm mechanisms.
Main Results:
- LA-UC selectively inhibited proliferation of melanoma cells (B16F10) with minimal impact on normal melanocytes.
- LA-UC induced G2/M cell cycle arrest by decreasing G2/M checkpoint proteins.
- LA-UC triggered caspase-dependent apoptosis, elevated mitochondrial ROS, disrupted mitochondrial membranes, and caused DNA damage in melanoma cells.
Conclusions:
- LA-UC demonstrates selective anti-melanoma activity.
- The compound induces apoptosis via G2/M cell cycle arrest, caspase activation, and mitochondrial ROS generation.
- LA-UC shows promise as a potential therapeutic candidate for melanoma treatment.
